Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) ...

AlphaQuest LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 177.1% in the fourth quarter, ...

Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31 ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ...

Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...